Homam Ibrahim1, Robert C Schutt1, Bashar Hannawi1, Timothy DeLao2, Colin M Barker1, Neal S Kleiman3. 1. Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas; Weill-Cornell Medical College, New York, New York. 2. Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas. 3. Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas; Weill-Cornell Medical College, New York, New York. Electronic address: nkleiman@houstonmethodist.org.
Abstract
BACKGROUND: Immature platelets are less responsive to the effects of antiplatelet drugs and contain messenger ribonucleic acid that is translationally active. They can be measured easily using an automated hematoanalyzer and reported as part of the complete blood count. OBJECTIVES: The purpose of this study was to determine the prognostic significance of elevated immature platelet count (IPC) in patients with coronary artery disease (CAD). METHODS: In this prospective cohort study in patients with CAD, patients underwent IPC measurement and were then followed up for the composite endpoint of major adverse cardiovascular events (MACE), defined as a composite of all-cause mortality, myocardial infarction, unplanned revascularization, or hospitalization for angina. For the purposes of analysis, patients were stratified into tertiles of IPC. RESULTS: Eighty-nine patients were followed up for a median of 31 months. Stratification to the high IPC tertile was associated with higher rates of MACE compared with the intermediate and low tertiles (60% vs. 24% vs. 16%, respectively; p < 0.001). Time-dependent receiver-operating characteristic analysis revealed that an IPC level ≥7,632 platelets/μl was 70.7% sensitive and 82.1% specific for MACE. After adjustment for age, admission diagnosis, index revascularization, heart failure, smoking, hematocrit, and baseline platelet count, patients with an IPC level ≥7,632 platelets/μl were more likely to experience a MACE (hazard ratio: 4.65; 95% confidence interval: 1.78 to 12.16; p < 0.002). CONCLUSIONS: IPC is a novel biomarker for MACE risk stratification in patients with CAD. Future studies should focus on the utilization of this marker for individualized antiplatelet therapy.
BACKGROUND: Immature platelets are less responsive to the effects of antiplatelet drugs and contain messenger ribonucleic acid that is translationally active. They can be measured easily using an automated hematoanalyzer and reported as part of the complete blood count. OBJECTIVES: The purpose of this study was to determine the prognostic significance of elevated immature platelet count (IPC) in patients with coronary artery disease (CAD). METHODS: In this prospective cohort study in patients with CAD, patients underwent IPC measurement and were then followed up for the composite endpoint of major adverse cardiovascular events (MACE), defined as a composite of all-cause mortality, myocardial infarction, unplanned revascularization, or hospitalization for angina. For the purposes of analysis, patients were stratified into tertiles of IPC. RESULTS: Eighty-nine patients were followed up for a median of 31 months. Stratification to the high IPC tertile was associated with higher rates of MACE compared with the intermediate and low tertiles (60% vs. 24% vs. 16%, respectively; p < 0.001). Time-dependent receiver-operating characteristic analysis revealed that an IPC level ≥7,632 platelets/μl was 70.7% sensitive and 82.1% specific for MACE. After adjustment for age, admission diagnosis, index revascularization, heart failure, smoking, hematocrit, and baseline platelet count, patients with an IPC level ≥7,632 platelets/μl were more likely to experience a MACE (hazard ratio: 4.65; 95% confidence interval: 1.78 to 12.16; p < 0.002). CONCLUSIONS: IPC is a novel biomarker for MACE risk stratification in patients with CAD. Future studies should focus on the utilization of this marker for individualized antiplatelet therapy.
Authors: Elena Y Senchenkova; Janice Russell; Alper Yildirim; D Neil Granger; Felicity N E Gavins Journal: Hypertension Date: 2019-04 Impact factor: 10.190
Authors: Adi Lador; Dorit Leshem-Lev; Galia Spectre; Aryeh Abelow; Ran Kornowski; Eli I Lev Journal: J Thromb Thrombolysis Date: 2017-10 Impact factor: 2.300
Authors: Evangelos K Oikonomou; Theodoros I Repanas; Christos Papanastasiou; Damianos G Kokkinidis; Michael Miligkos; Attila Feher; Dipti Gupta; Polydoros N Kampaktsis Journal: Thromb Res Date: 2016-09-24 Impact factor: 3.944
Authors: Matthias K Freynhofer; Liana Iliev; Veronika Bruno; Miklos Rohla; Florian Egger; Thomas W Weiss; Wolfgang Hübl; Martin Willheim; Johann Wojta; Kurt Huber Journal: Thromb Haemost Date: 2017-02-23 Impact factor: 5.249